Dr Daniel Utzschneider Receives 2023 Ramaciotti Health Investment Grant

One of the biggest health issues globally, cancer affects millions of people worldwide, and despite the success of therapies like 'checkpoint blockade,' not all patients benefit, highlighting the need for innovative approaches. The immune system, particularly T cells, often becomes functionally exhausted in response to cancer which facilitates disease progression.

To address this challenge, Dr Utzschneider, an internationally recognised leader in the study of T cell biology in response to cancer and chronic infections, will use advanced technology to screen for regulators that impact T cell responses to cancer.

“We have established a CRISPR screen platform, which unlike conventional screens, can select T cells based on their functionality and localisation, allowing us to identify targets that impact T cell quality rather than quantity,” said Dr Utzschneider.

Ultimately, our aim is to unveil promising therapeutic targets to enhance cancer treatments or improve existing therapies.

Dr Utzschneider thanked Perpetual, the Trustee of the Clive and Vera Ramaciotti Foundations, for their support in achieving this goal.

“I am grateful to Perpetual and Ramaciotti Foundations for funding this important work. Their generosity makes a substantial impact on advancing health and medical research, and the 2023 Ramaciotti Health Investment grant will help us progress research which may eventually lead to new or improved ways to treat cancer,” said Dr Utzschneider.

Awarded by Perpetual, Trustee of the Clive and Vera Ramaciotti Foundations, on the recommendation of a dedicated Scientific Advisory Committee, the Ramaciotti Health Investment grants support health or medical research that has the potential path to clinical application within five years. The grants aim to provide research support for an autonomous early-career investigator who is taking, or has recently taken, a substantive position.

This article was originally published on 21 November 2023 by the Peter Doherty Institute for Infection & Immunity.

The Doherty Institute is a joint venture between the University of Melbourne and The Royal Melbourne Hospital.